Enzyme replacement therapy during pregnancy and breastfeeding in late-onset Pompe disease Authors: Magdalena Bachmann, David Kasper, Sabine Scholl-Bürgi, Julian Margreitter, Alexander Höller, Wolfgang Löscher, Daniela Karall, Thomas Zöggeler Published: 2025 ABSTRACT BackgroundPompe disease is an autosomal recessively inherited lysosomal storage disorder, caused by enzyme deficiency of acid alpha-glucosidase (GAA). This deficiency leads to the accumulation of glycogen in lysosomes and subsequent muscle dysfunction, thus affecting heart and skeletal muscle. Since 2006, enzyme replacement therapy (ERT) is available. The use of ERT during pregnancy and lactation remains a topic of concern due to limited data on the safety of ERT during these periods. Despite this, some previous case reports suggest that ERT is safe during pregnancy and lactation.Case presentationIn this case series, we collected the data on five pregnancies in three women with late-onset Pompe disease who were on ERT and continued it during pregnancy and lactation. In two of the children, during the lactation period activity levels of alglucosidase alfa were measured in breastmilk on dried blood spots.ConclusionThese case reports add to the literature experience by presenting the information on five so far not reported pregnancies in three women with late-onset Pompe disease, where ERT was continued during pregnancy and lactation. The results showed that acid alpha-glucosidase activity in milk from a woman with Pompe disease in two different breastfeeding periods was in the same range as acid alpha glucosidase activity in milk from five healthy women. As for the outcome in the five children, all have age-appropriated growth and development, confirming that ERT in this cohort was feasible and safe. These findings reinforce the safety of continuing ERT during pregnancy and breastfeeding in Pompe disease. Breastfeeding not only is the age adequate nutrition but also supports the well-being and development of the child as well as benefits maternal health. The value of breastfeeding being the recommended form of nutrition for infants cannot be emphasized enough. Thus, breastfeeding has to be especially supported in situations where there is a chronic disease/condition or medication. Further reports and appropriate guidelines are needed to soundly provide good advice to women with Pompe disease (or Morbus Pompe) during pregnancy and breastfeeding. Background Pompe disease (also known as glycogen storage disease type II), an autosomal recessively inherited lysosomal storage disease of glycogen accumulation, is caused by enzyme deficiency of acid alpha-glucosidase (GAA) [1–3]. The lysosomal accumulation of glycogen leads to muscle cell dysfunction [1–3]. The phenotypic presentation ranges from proximal skeletal muscle weakness to cardiomyopathy with respiratory insufficiency [1–3]. The symptoms of Pompe disease are often nonspecific. [1–3]The disease can be classified into different phenotypic forms based on the severity and timing of symptom onset [1–3]. The infantile form, if untreated, is usually fatal due to heart failure in the first few years of life, often before the age of reproduction is reached [1–3]. In contrast, the late-onset form presents with a wide spectrum of symptoms, mainly due to deterioriation of muscle, i.e. (cardio)myopathy, respiratory insufficiency, walking unavailability, truncal weakness [1–3]. The women described in this case report exhibit this late-onset form. Since 2006, enzyme replacement therapy (ERT) with alglucosidase alfa is in use [1–4]. According to European Medicines Agency (EMA) approval of alglucosidase alfa, ERT administration during pregnancy should be avoided unless the woman‘s clinical condition requires treatment, due to limited data and possible reproductive toxicity observed in animal studies [5]. However, drug administration during breastfeeding may be considered, as no clinical effects on the infant are expected despite evidence of low concentrations of the drug in breast milk [5–8]. Up until now, there is only a limited number (about 10–20 pregnancies) of case reports available regarding pregnancy under ERT in late-onset Pompe disease [6, 9–15]. Firstly, in 2011 a patient was reported who continued ERT during pregnancy and lactation in weight-adjusted doses (20 mg/kg every other week intravenously) without any noted side effects on the child [6]. The child´s development was appropriate for age as monitored by regular clinical examination in the first year of life [6]. Since then, further cases (about 10–20) have been published, without evidence of any adverse effect in fetuses exposed to ERT, and adequate fetal growth [6, 9–12, 15]. In addition, the continuation of ERT during pregnancy will mean a positive effect for the expectant mothers with Pompe disease [6, 10, 13, 15]. The data on the continuation of ERT during breastfeeding is even more limited [6, 15]. Low levels of alglucosidase alfa were found in breast milk, with a peak 2.5 hours after infusion, which turns to preinfusion-levels within twenty-four hours [6]. In this study we report additional five pregnancies in three women with Pompe disease where ERT was continued during pregnancy and lactation. Additionally, in two cases the activity of alpha-glucosidase was measured in breastmilk. The aim of this study is to add these cases and the outcome of the children to literature. Case presentations In this present case series, we included three women with the diagnosis of Pompe disease and enzyme replacement therapy during pregnancy and breastfeeding. Patient 1 Patient 1 was diagnosed with Pompe disease at the age of 11 years based on a muscle biopsy. At the age of 7 years, the patient first experienced symptoms that could be associated with Pompe disease. She experienced muscle weakness during sports, for example, when sprinting. Furthermore, she reported urinary incontinence and speech problems, which is why she was under speech therapy care. Medication therapy with alglucosidase alfa was started at the age of 12 years (initially as a participant of the clinical study) [2]. The patient reported no side effects during treatment. At the age of 30, patient 1 gave birth to a child after an uneventful pregnancy. The boy was born by a planned Caesarean section with 37 + 0 weeks of pregnancy with a birth weight of 3250 g (percentile 15–50) and a length of 48 cm (percentile 15–50) [16, 17]. The ERT, which had been started at age 12 years, was continued without side effects throughout pregnancy and the child´s birth, once every other week with a dosage of 1300 mg intravenously (20 mg/kg). From birth, the child (CHILD 1–1) was exclusively breastfed and complementary feeding was introduced after about 6 months. With 6 months he had a weight of 10.7 kg (percentile > 97), a length of 71 cm (percentile 85–97) and a head circumference of 47 cm (percentile > 97) (see Fig. 1) [16–18]. On 31 OCT 2024, he is 2 year and 2 months old and shows adequate development.Fig. 1Percentiles for weight, length and head circumference of the children, CHILD 1–1, CHILD 2–1. Percentiles (x-axis: age (years)) for weight (y-axis: weight (kg)), length (y-axis: length (cm)) and head circumference (y-axis: head circumference (cm)) for four of the five breastfed children of two women with pompe disease in the first 6 to 12 months [16–18]. All four show appropriate for age thriving and psychomotor development Percentiles for weight, length and head circumference of the children, CHILD 1–1, CHILD 2–1. Percentiles (x-axis: age (years)) for weight (y-axis: weight (kg)), length (y-axis: length (cm)) and head circumference (y-axis: head circumference (cm)) for four of the five breastfed children of two women with pompe disease in the first 6 to 12 months [16–18]. All four show appropriate for age thriving and psychomotor development Patient 2 Patient 2 was diagnosed with Pompe disease at the age of 22 years on the basis of a muscle biopsy followed by genetic confirmation. The patient reported symptoms such as fatigue; because of oversleeping she was often late at work. Her legs buckled when climbing stairs from the 2nd floor upwards or during sports. No diagnosis could be found for almost a year. Six months after diagnosis, therapy with alglucosidase alfa (20 mg/kg every other week intravenously) was initiated and has not been interrupted since. The patient reports no adverse drug effects under therapy. Patient 2 currently has 3 healthy children. ERT was changed in the first trimester of pregnancy of child 3 to the newer formulation of ERT avalglucosidase alfa (20 mg/kg every other week intravenously). No side effects have been reported under this therapy either. Child 1 (CHILD 2–1) Child 1 (male) was born at 41 + 1 weeks of pregnancy via planned Caesarean section with a birth weight of 4115 g (percentile 85–97) and a length of 53 cm (percentile 85–97) [16, 17]. Pregnancy and birth were uneventful. He was breastfed, complementary feeding was started at about six months. At 6 months, he had a weight of 7.9 kg (percentile15-50), a length of 68.5 cm (percentile 50–85) and a head circumference of 44 cm (percentile 50–85) (see Fig. 1) [16–18]. His development is appropriate for age. In this child, activity levels of alglucosidase alfa were measured in breastmilk (see Fig. 2). The determination of acid alpha-glucosidase activity (µmol/L/h) was measured using tandem mass spectrometry as described in Metz et al. 2011 [19]. On 31 OCT 2024 he is 4 years and 1 month old.Fig. 2Measurements of acid alpha-glucosidase (GAA) enzyme activity in [µmol/L/h] [19] in mature human milk collected on dried blood spots. Samples from child 1 (dots = •) and child 3 (crosses = x) after enzyme replacement therapy infusion (ERT) given to the mother, the collection time on the x-axis is given in hours [h] after ERT to the mother, red shaded area: reference range from samples from five healthy lactating women, with several three and four samples each, measured in duplicates; lower and upper red line correspond to lower (4.1 µmol/L/h) and upper (7.5 µmol/L/h) range of acid alpha-glucosidase activity in milk samples measured Measurements of acid alpha-glucosidase (GAA) enzyme activity in [µmol/L/h] [19] in mature human milk collected on dried blood spots. Samples from child 1 (dots = •) and child 3 (crosses = x) after enzyme replacement therapy infusion (ERT) given to the mother, the collection time on the x-axis is given in hours [h] after ERT to the mother, red shaded area: reference range from samples from five healthy lactating women, with several three and four samples each, measured in duplicates; lower and upper red line correspond to lower (4.1 µmol/L/h) and upper (7.5 µmol/L/h) range of acid alpha-glucosidase activity in milk samples measured Child 2 (CHILD 2–2) Child 2 (female) was born vaginally at 40 + 6 weeks of pregnancy with a birth weight of 3570 g (percentile 50–85) and a length of 55 cm (percentile > 97) [16, 17]. During this pregnancy, the mother reports episodes of lumbar pain. Child 2 was exclusively breastfed for about 6 months, complementary feeding was then started. In this child, activity levels of alglucosidase alfa were not measured in breastmilk (see Fig. 3). At 12 months, she had a weight of 8.7 kg (percentile 15–50), a length of 74 cm (percentile 50) and a head circumference of 46 cm (percentile 50–85) [16–18]. Her development is appropriate for age. On 31 OCT 2024 she is 2 years and 6 months old.Fig. 3Percentiles for weight, length and head circumference of the children, CHILD 2–2, CHILD 2–3. Percentiles (x-axis: age (years)) for weight (y-axis: weight (kg)), length (y-axis: length (cm)) and head circumference (y-axis: head circumference (cm)) for four of the five breastfed children of two women with pompe disease in the first 6 to 12 months [16–18]. All four show appropriate for age thriving and psychomotor development Percentiles for weight, length and head circumference of the children, CHILD 2–2, CHILD 2–3. Percentiles (x-axis: age (years)) for weight (y-axis: weight (kg)), length (y-axis: length (cm)) and head circumference (y-axis: head circumference (cm)) for four of the five breastfed children of two women with pompe disease in the first 6 to 12 months [16–18]. All four show appropriate for age thriving and psychomotor development Child 3 (CHILD 2–3) Child 3 (female) was born at 40 + 4 weeks of pregnancy with a birth weight of 3455 g (percentile 50–85) and a length of 53 cm (percentile > 97) [16, 17]. Pregnancy and birth were uneventful. She was breastfed in the first months of life. At 4 months, she had a weight of 6.5 kg (percentile 50–85), a length of 63.2 cm (percentile 50–85) and a head circumference of 41.8 cm (percentile 50–85) (see Fig. 3) [16–18]. In this child, activity levels of alglucosidase alfa were measured in breastmilk (see Fig. 2). [19] Her development is appropriate for age. On 31 OCT 2024 she is 9 months old. The enzyme replacement therapy was continued during pregnancy and lactation period for all three children at the same dosage. Patient 2 reports no side effects of enzyme replacement therapy during pregnancy and breastfeeding. Patient 3 For Patient 3 data are incomplete (lost to follow-up). The patient was diagnosed with Pompe disease, when she was around 25 years old. Around 3.5 years after diagnosis she started ERT. When she was around 30 years old, she gave birth to a baby. There was a pause in treatment prior to the date of childbirth. Reinitiation of ERT occurred 5 weeks after birth. Pregnancy and birth were uneventful. The child was exclusively breastfed for some months. Thriving and development of the child were reported to be adequate for age. Discussion Pompe disease is a lysosomal storage disorder with a progressive (cardio)muscular course and a shortened life expectancy [1–3]. Since 2006, an enzyme replacement therapy is available, which improves symptoms (improved walking distances, stabilization of pulmonary function, improved muscle strength) and through that quality of life and general condition [1–3, 20]. Thus, similar to other inherited metabolic disorders, ongoing medication/ERT in pregnancy and breastfeeding has become an issue [21–24]. There are no specific guidelines for using ERT in pregnancy and lactation period, but there exist some case reports describing individualized management of pregnant women with Pompe disease [6, 7, 10, 12, 13, 15, 25, 26]. In their study, Yanagihara et al. compared 15 previously published case reports of patients with late-onset Pompe disease and pregnancy outcomes during ERT, in addition to presenting one new case described in their paper, resulting in a total of 16 case reports encompassing 20 pregnancies [26]. In approximately half of the reported pregnancies, ERT was continued throughout the entire gestational period, whereas in the remaining cases, therapy was temporarily discontinued for varying durations during pregnancy and, in some instances, beyond. Clinical improvement postpartum or within several months postpartum was observed in approximately 75% of the cases [26]. Lots of reports described the birth of a healthy infant; however, data regarding the long-term development of these children remain sparse [6, 10, 12, 13, 15, 26]. In most case reports where this information is provided, treatment with alglucosidase alfa is reported [6, 9, 10, 12, 15]. In contrast, data on the use of avalglucosidase alfa and the combination therapy cipaglucosidase alfa with miglustat during pregnancy and lactation are scarce or absent - likely due to the relatively recent approval of these newer ERT options [8, 26, 27]. For alglucosidase alfa there are about 10–20 reported cases of pregnancy and breastfeeding. For avalglucosidase alfa, the newer enzyme formulation for Pompe disease, there are even fewer informations available [8]. Avalglucosidase alfa is available since 2022. It has a higher affinity to Mannose-6-phosphate receptor [4]. There is one case reported where the infant was breastfed while the mother was receiving avalglucosidase alfa [8, 26]. We report three women with Pompe disease, who safely continued ERT during pregnancy and breastfeeding. In summary, in patient 1 (one child), patient 2 (three children) and patient 3 (one child), enzyme replacement therapy was continued during pregnancy and breastfeeding without complications and good outcome for the children. The amount of acid alpha-glucosidase measured in two sample series of breastfed children of patient 2 showed acid alpha-glucosidase activity in breastmilk in the range of acid alpha-glucosidase in breastmilk of control samples, i.e. milk from women without Pompe disease. The amount of acid alpha-glucosidase delivered in breast milk, is not different and thus irrelevant. Additionally, even a larger amount would be digested in the acidic environment of the stomach and gastrointestinal tract of the child, and thus would not enter the child`s bloodstream [28]. Similarly, ERT (Imiglucerase) is used during pregnancy and breastfeeding in patients with Gaucher disease Type 1. Here, there are data on more than 150 patients, continued ERT treatment is beneficial to avoid complications during pregnancy, childbirth and breastfeeding [22, 23, 29]. As a side note, in Gaucher disease successful pregnancies have also been reported during substrate reduction therapy with eliglustat, even though eliglustat is not yet approved during pregnancy due to limited data [24]. It has to be considered, that all ERT are proteins, thus, they have to be delivered intravenously. Pharmacokinetically, they will be digested if given enterally – also in the gastrointestinal tract of the fetus and breastfed child. They are large molecules ( > 200 kDa) and do not pass the blood-milk-barrier [19, 28]. Regardless of the child being a heterozygous carrier or even a homozygous affected, the enzyme replacement therapy will most probably not reach its blood stream and – even if minimal amount were to reach the blood stream – not cause a deleterious effect [7, 28, 30]. We could show this in two of the children (CHILD 2–1, and CHILD 2–3), where enzyme activity (acid alpha-glucosidase activity) was measured in milk sampled on dried blood spots: the acid alpha-glucosidase activity in breastmilk from Patient 2 with Pompe disease in two different breastfeeding periods (Child 2–1 and Child 2–3) was in the same range as acid alpha-glucosidase activity in the breastmilk from five healthy women (without Pompe disease) (i.e. control samples), there was no difference in the measured enzyme activity in breastmilk from women with and without Pompe disease (see Fig. 2). [19] Therefore, it can be concluded, that the enzyme is not enriched in breast milk. Thus, ERT is prone to be safe both during pregnancy and breastfeeding. Additionally, even a larger amount would be digested in the acidic environment of the stomach and gastrointestinal tract of the child, and thus would not enter the child`s bloodstream [28]. As ERT of women with Pompe disease should not be interrupted while pregnant, the knowledge that ERT is safe is essential. Breastfeeding is recognized as beneficial for both breastfeeding women as well as their children. The underlying advantages should definitely be warranted also for mother-baby-dyads, where the mother is affected by a lysosomal storage disorder under ERT, in our cases, Pompe disease [6, 15, 31]. Conclusion With this case series we add our experience to the few cases already reported in the literature. We confirm, there is no evidence of a negative effect on the child if ERT is continued during pregnancy and breastfeeding in women with Pompe disease. Fetal and child growth and development in the first years of life were age-adequate in all five children reported here. As breastfeeding is the recommended nutrition for babies, according to international guidelines for infant and young child feeding, it should be available and recommended also for children of mothers with Pompe disease [15, 30, 32]. We would like to emphasize the importance of reporting further women with lysosomal storage disorders receiving ERT during pregnancy and breastfeeding to fortify the so far scarce experiences. Nevertheless, feasibility and safety of this recommendation has been shown. In the future, guidelines for using ERT in women with Pompe disease and other lysosomal storage disorders during pregnancy and breastfeeding should be available.